[PDF][PDF] Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L
Y Urata, N Katakami, S Morita, R Kaji… - Journal of Clinical …, 2016 - clf1.medpagetoday.com
Y Urata, N Katakami, S Morita, R Kaji, H Yoshioka, T Seto, M Satouchi, Y Iwamoto…
Journal of Clinical Oncology, 2016•clf1.medpagetoday.comPurpose The epidermal growth factor receptor (EGFR) tyrosine kinase has been an
important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors
(TKIs) are currently approved, and both gefitinib and erlotinib are the most well-known first-
generation EGFR-TKIs. This randomized phase III study was conducted to investigate the
difference between these two EGFR-TKIs.
important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors
(TKIs) are currently approved, and both gefitinib and erlotinib are the most well-known first-
generation EGFR-TKIs. This randomized phase III study was conducted to investigate the
difference between these two EGFR-TKIs.
Purpose
The epidermal growth factor receptor (EGFR) tyrosine kinase has been an important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors (TKIs) are currently approved, and both gefitinib and erlotinib are the most well-known first-generation EGFR-TKIs. This randomized phase III study was conducted to investigate the difference between these two EGFR-TKIs.
clf1.medpagetoday.com
以上显示的是最相近的搜索结果。 查看全部搜索结果